Mycoplasma in Poultry: Clinical Signs, Eye Infections, Treatment, and Control
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Avian mycoplasmosis, primarily caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), significantly impacts poultry economics through reduced egg production, feed efficiency, and increased mortality, with vertical and horizontal transmission routes being critical for persistence.
- Clinical signs range from respiratory distress (rales, cough, sneezing) and ocular manifestations (conjunctivitis, periocular swelling, epiphora) to infectious synovitis (lameness, joint swelling) and eggshell apex abnormalities (EAA) in laying hens.
- Definitive diagnosis relies on culture, though it is technically demanding; molecular methods like PCR and qPCR offer superior sensitivity and specificity for detecting MG and MS, while serological tests (SPA, ELISA) are valuable for flock-level surveillance.
- Antimicrobial treatment options include macrolides, pleuromutilins, tetracyclines, and fluoroquinolones, but antimicrobial resistance is an emerging concern, necessitating susceptibility testing and judicious use.
- Control strategies emphasize stringent biosecurity, eradication programs for breeder flocks, and strategic vaccination using live attenuated (e.g., ts-11, F-strain for MG; MS-H for MS) or inactivated vaccines to mitigate clinical signs and production losses.
Introduction
Avian mycoplasmosis, caused primarily by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS), represents a group of economically significant diseases affecting poultry worldwide [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. These bacteria belong to the class Mollicutes, characterized by the absence of a cell wall, which confers intrinsic resistance to beta-lactam antimicrobials and necessitates specialized culture techniques [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>]. MG is the classical etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys, while MS causes infectious synovitis, respiratory disease, and eggshell apex abnormality (EAA) [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>]. The economic impact of these infections stems from reduced egg production, decreased feed efficiency, increased mortality, and carcass condemnation at slaughter [<a href="#ref-7">7</a>, <a href="#ref-8">8</a>]. Vertical transmission via the egg (transovarian passage) is a critical feature of mycoplasma epidemiology, allowing persistence of infection through successive generations in breeding stock [<a href="#ref-9">9</a>, <a href="#ref-10">10</a>]. Horizontal transmission occurs through aerosolized respiratory secretions, direct contact, and contaminated fomites [<a href="#ref-11">11</a>, <a href="#ref-12">12</a>]. This article provides a detailed examination of the clinical presentation, diagnostic approaches, therapeutic options, and control strategies for avian mycoplasmosis, with specific emphasis on ocular manifestations.
Etiology and Species
The genus Mycoplasma encompasses over 100 species, but relatively few are primary pathogens of poultry [<a href="#ref-13">13</a>, <a href="#ref-14">14</a>]. Mycoplasma gallisepticum is the most virulent and economically impactful, causing CRD in chickens and sinusitis in turkeys [<a href="#ref-15">15</a>, <a href="#ref-16">16</a>]. Mycoplasma synoviae is associated with both respiratory disease and infectious synovitis, and it is increasingly recognized as a cause of EAA in laying hens [<a href="#ref-6">6</a>, <a href="#ref-17">17</a>]. Other species of lesser pathogenic significance include Mycoplasma meleagridis in turkeys and Mycoplasma iowae in turkeys [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>]. Mycoplasma pullorum is frequently isolated from poultry but its pathogenic role remains incompletely understood; it is often found as a co-infecting agent alongside MS in cases of EAA [<a href="#ref-20">20</a>]. The avian respiratory tract is colonized by a complex community of mycoplasmas, and commensal species may complicate diagnostic interpretation [<a href="#ref-21">21</a>].
Clinical Signs and Pathogenesis
Respiratory Manifestations
MG infection typically begins with colonization of the tracheal mucosa via specialized adhesion molecules, including GapA and CrmA, which mediate attachment to sialic acid receptors on ciliated epithelial cells [<a href="#ref-22">22</a>, <a href="#ref-23">23</a>]. Adherence is followed by ciliostasis, epithelial cell damage, and an influx of inflammatory cells, predominantly lymphocytes and plasma cells [<a href="#ref-24">24</a>, <a href="#ref-25">25</a>]. The resulting pathological changes include tracheal mucosal thickening, lymphoid follicle formation, and luminal exudation [<a href="#ref-26">26</a>, <a href="#ref-27">27</a>]. Clinically, infected birds exhibit rales (tracheal rattling), cough, sneezing, nasal discharge, and dyspnea [<a href="#ref-28">28</a>, <a href="#ref-29">29</a>]. These signs are often exacerbated by concurrent infections with Escherichia coli, infectious bronchitis virus (IBV), Newcastle disease virus (NDV), or Ornithobacterium rhinotracheale [<a href="#ref-30">30</a>, 31, 32]. The exacerbation of MG lesions in the presence of IBV is a classic example of a multi-factorial respiratory disease complex [33, 34]. In turkeys, infraorbital sinus swelling is a characteristic finding, often progressing to caseous exudate accumulation within the sinuses [35, 36].
Ocular Infections
Ocular involvement in avian mycoplasmosis is a distinct and important clinical entity [<a href="#ref-9">9</a>, 37]. In chickens, MG infection can cause conjunctivitis, periocular swelling, and epiphora (excessive lacrimation) [38, 39]. The conjunctival mucosa becomes hyperemic and edematous, and a serous to mucoid ocular discharge is frequently observed [40, 41]. In severe cases, caseous exudate may accumulate beneath the nictitating membrane. The pathogenesis of ocular mycoplasmosis involves direct bacterial adherence to conjunctival epithelial cells, triggering a local pro-inflammatory cytokine response. Studies in house finches (Haemorhous mexicanus), a natural model for MG-induced conjunctivitis, have demonstrated that inflammatory cytokine signaling, particularly interleukin-1 beta (IL-1B), correlates strongly with conjunctival bacterial load and clinical severity. In poultry, ocular signs may be subtle and overshadowed by more prominent respiratory symptoms, but they remain important for clinical diagnosis. Experimental challenge models using ocular or aerosol routes have demonstrated that conjunctival colonization can occur independently of deep respiratory infection, suggesting that the eye may serve as a portal of entry and a site of primary replication [46, 47].
Synovial and Reproductive Manifestations
MS infection classically presents as infectious synovitis, characterized by lameness, hock joint swelling, breast blisters, and sternal bursitis [48, 49]. Affected birds exhibit reluctance to move, reduced feed intake, and stunted growth [50, 51]. Postmortem examination reveals viscous, turbid synovial fluid in the joints and tendon sheaths, which may progress to caseous exudation [52, 53]. In laying hens, MS is also a causative agent of EAA, a condition in which the eggshell apex (the pointed end) becomes thin, translucent, and prone to breakage [<a href="#ref-6">6</a>, 54]. The mechanism involves colonization of the oviduct, particularly the shell gland (uterus), leading to defective calcium deposition in the shell matrix [55, 56]. Affected eggs exhibit a distinct rough or ridged band at the apex, and such eggs are downgraded or discarded, causing substantial economic losses [57, 58].
Diagnostic Approaches
Clinical and Pathological Examination
Presumptive diagnosis of mycoplasmosis is based on clinical signs, postmortem lesions, and flock history [59, 60]. Gross lesions include catarrhal to caseous tracheitis, airsacculitis (thickened, cloudy, or foamy air sacs), and fibrinous pericarditis [61, 62]. Joint lesions show synovial thickening and exudation. Histopathological examination reveals lymphoplasmacytic infiltration, epithelial hyperplasia, and goblet cell metaplasia in the tracheal mucosa [64, 65]. Immunohistochemistry (IHC) using anti-MG antibodies can confirm the presence of bacterial antigen in tissue sections, particularly along the ciliated border of the tracheal epithelium.
Culture
Isolation of mycoplasmas from clinical specimens remains the definitive diagnostic method but is technically demanding and time-consuming [67, 68]. Samples (tracheal swabs, choanal swabs, synovial fluid, or lung tissue) are inoculated into liquid media such as Frey's medium or modified Edward's medium supplemented with horse serum, yeast extract, glucose, and nicotinamide adenine dinucleotide (NAD) for MS [69, 70]. Incubation is performed at 37°C in a microaerophilic atmosphere for up to 14 days. Positive cultures show a color change from red to yellow (due to glucose fermentation) and the formation of characteristic "fried-egg" colonies on solid media [72, 73]. However, culture is insensitive compared to molecular methods, and samples with low bacterial loads or prior antimicrobial exposure may yield false negatives [74, 75].
Serology
Serological testing is widely used for flock-level screening and monitoring [76, 77]. The serum plate agglutination (SPA) test is a rapid, inexpensive method for detecting antibodies against MG and MS, but it lacks specificity and may yield false positives due to cross-reactivity with other mycoplasma species or vaccine strains [78, 79]. The enzyme-linked immunosorbent assay (ELISA) provides quantitative antibody titers and is more specific than SPA, making it suitable for large-scale surveillance [80, 81]. Hemagglutination inhibition (HI) tests are less commonly used but offer high specificity for strain differentiation. Interpretation of serological results requires knowledge of vaccination history, because live vaccine strains (e.g., ts-11, F-strain, 6/85) induce antibody responses that are indistinguishable from field infection in some assays [83, 84].
Molecular Diagnostics
Polymerase chain reaction (PCR) has become the cornerstone of mycoplasma diagnosis in modern poultry medicine due to its high sensitivity, specificity, and rapid turnaround time [<a href="#ref-2">2</a>, 85]. Conventional and real-time PCR assays targeting the 16S rRNA gene, the mgc2 gene (for MG), and the vlhA gene (for MS) are widely used [86, 87]. Multiplex PCR formats allow simultaneous detection of MG, MS, and other respiratory pathogens from a single sample [88, 89]. Quantitative real-time PCR (qPCR) provides bacterial load data, which can be useful for assessing the severity of infection and monitoring therapeutic response [90, 91]. Advanced genotyping methods, including multilocus sequence typing (MLST) and vlhA gene sequencing, enable strain discrimination for epidemiological investigations [92, 93]. Isothermal amplification techniques, such as recombinase polymerase amplification (RPA) and loop-mediated isothermal amplification (LAMP), have been developed for field-deployable detection and show promise for point-of-care diagnostics [94, 95, 96]. High-resolution melting analysis and CRISPR-based detection platforms further expand the molecular diagnostic toolkit [97, 98].
flowchart TD
A["Clinical signs: respiratory, ocular, synovial"] --> B{"Diagnostic sample collection"}
B --> C["Tracheal / choanal swab"]
B --> D["Synovial fluid / joint swab"]
B --> E["Serum"]
C --> F{"Laboratory testing"}
D --> F
E --> G["Serology: SPA, ELISA, HI"]
F --> H["Culture: Frey's medium, 7-14 days"]
F --> I["PCR: 16S rRNA, mgc2, vlhA"]
F --> J["qPCR for bacterial load"]
I --> K["Genotyping: MLST, sequencing"]
H --> L["Identification: colony morphology, MALDI-TOF"]
G --> M{"Interpretation"}
M --> N["Positive → Vaccination history? Field strain?"]
M --> O["Negative → Consider seroconversion window"]
K --> P["Phylogenetic analysis"]Treatment
Antimicrobial Therapy
Treatment of mycoplasmosis in poultry is challenging because of the intrinsic resistance of Mollicutes to cell wall-active agents (beta-lactams, glycopeptides) and the propensity for antimicrobial resistance (AMR) development [99, 100]. Macrolides (tylosin, tilmicosin, erythromycin), pleuromutilins (tiamulin), tetracyclines (chlortetracycline, doxycycline, oxytetracycline), fluoroquinolones (enrofloxacin), and lincosamides (lincomycin) are commonly used classes [101, 102]. Tiamulin administered at 25 mg/kg body weight for 5 consecutive days has demonstrated significant efficacy in reducing clinical signs and bacterial loads in MG-infected broilers. Tilmicosin at 20 mg/kg for 5 days also significantly reduces respiratory lesions and bacterial numbers. However, surveillance data indicate that AMR is an emerging concern. A study of MG isolates collected in Italy between 2010 and 2020 reported that 79.1% of isolates showed enrofloxacin MIC values of 8 microgram/mL or higher, indicating reduced susceptibility, while a trend toward renewed susceptibility to macrolides and tiamulin was observed. In MS, mutations in the 23S rRNA gene conferring macrolide resistance, and polymorphisms in gyrA, gyrB, parC, and parE genes conferring fluoroquinolone resistance, have been characterized. Combination therapy, such as tiamulin plus chlortetracycline, has shown enhanced efficacy in experimental models. Aivlosin (a macrolide) in combination with zinc oxide nanoparticles has also been evaluated for treating MG and ORT co-infections, showing improved clinical outcomes and reduced tissue residues. Antimicrobial susceptibility testing via broth microdilution is recommended to guide therapy, although it is labor-intensive and not routinely available in diagnostic practice [108, 109].
Supportive Care
In addition to antimicrobials, supportive care including optimized ventilation, reduced stocking density, and correction of nutritional deficiencies can improve outcomes. Co-infections with other respiratory pathogens should be addressed through appropriate vaccination and management programs.
Control and Prevention
Biosecurity and Eradication
Biosecurity is the foundation of mycoplasma control [<a href="#ref-18">18</a>, 112]. Because vertical transmission is a major route, the establishment and maintenance of MG- and MS-free breeder flocks is a primary goal. This requires rigorous surveillance, including regular serological and molecular testing, and the culling of positive flocks [114, 115]. Quarantine protocols for incoming birds, strict all-in/all-out production systems, and decontamination of facilities between flocks are essential. Rodent control and minimization of contact with wild birds reduce the risk of introduction [117, 118].
Vaccination
Vaccination is widely used in commercial layers and breeders to reduce clinical signs and production losses [119, 120]. Live attenuated vaccines include the F-strain, ts-11, and 6/85 for MG, and the MS-H strain for MS [121, 122, 123]. The F-strain is highly immunogenic but retains some virulence and can spread to contact birds. The ts-11 strain is temperature-sensitive and less transmissible, but field strains can breakthrough in vaccinated flocks, necessitating molecular differentiation [125, 126]. MS-H is a live attenuated vaccine derived from the Australian 86079/7NS strain and is widely used for MS control. Reversion to virulence and reacquisition of wild-type genotypes in the obgE, oppF, and gapdh genes have been documented in field reisolates, but these reisolates do not appear to cause increased clinical severity in contact birds. Inactivated (bacterin) vaccines, including bivalent MG/MS formulations and pentavalent vaccines combined with Salmonella antigens, have been developed and evaluated in SPF and commercial settings, demonstrating high protective efficacy [129, 130, 131]. Recombinant vector vaccines, such as fowlpox virus-vectored MG vaccines, offer partial protection but may be less effective than traditional live vaccines in preventing clinical signs. The choice of vaccination program depends on the production system, the prevalence and strain of circulating mycoplasmas, and the regulatory framework.
Antimicrobial Stewardship
The use of antimicrobials for metaphylaxis or treatment should be guided by susceptibility data and strict withdrawal periods to prevent residues in meat and eggs [134, 135]. The development of rapid molecular assays for detecting resistance-associated mutations may facilitate targeted therapy. The pleuromutilin class, including tiamulin and novel derivatives like amphenmulin, represents a valuable option for combating resistant strains.
Conclusion
Avian mycoplasmosis remains a persistent challenge for the global poultry industry. The clinical spectrum of disease, from overt respiratory signs and ocular inflammation to subclinical egg production losses, reflects the complex interplay between mycoplasma virulence factors, host immune responses, and environmental stressors. Diagnostic strategies have moved from culture-based methods to PCR, qPCR, and genotyping, enabling rapid detection and strain characterization. Antimicrobial therapy, while essential for outbreak management, is constrained by AMR. Long-term control relies on a multi-faceted approach: rigorous biosecurity, eradication programs for breeder flocks, strategic vaccination, and prudent antimicrobial use. Continued research into the molecular mechanisms of pathogenesis, host-pathogen interactions, and vaccine development is necessary to mitigate the economic impact of these organisms.
Related Clinical & Scientific Guides
- Duck Diseases: A Comprehensive Overview for Veterinary Practitioners
- Salmonella Dublin in Cattle: Emerging Pathogen, Diagnostic Challenges, and Public Health Impact
- Mycoplasma Infections in Poultry: Vaccination Strategies and Control Programs